Due to the unbalanced IFN levels in the serum of severe COVID-19 patients, the effect of IFN-based therapies is limited mainly to the early stage of infection and only shows prophylactic potential (176, 187, 188). The gene discussed is IFNA1; the disease is COVID-19.